These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18375895)

  • 1. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
    Spurdle AB; Lakhani SR; Healey S; Parry S; Da Silva LM; Brinkworth R; Hopper JL; Brown MA; Babikyan D; Chenevix-Trench G; Tavtigian SV; Goldgar DE;
    J Clin Oncol; 2008 Apr; 26(10):1657-63. PubMed ID: 18375895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
    Chenevix-Trench G; Healey S; Lakhani S; Waring P; Cummings M; Brinkworth R; Deffenbaugh AM; Burbidge LA; Pruss D; Judkins T; Scholl T; Bekessy A; Marsh A; Lovelock P; Wong M; Tesoriero A; Renard H; Southey M; Hopper JL; Yannoukakos K; Brown M; Easton D; Tavtigian SV; Goldgar D; Spurdle AB;
    Cancer Res; 2006 Feb; 66(4):2019-27. PubMed ID: 16489001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-based analysis of BRCA1 and BRCA2 gene alterations.
    Bonatti F; Pepe C; Tancredi M; Lombardi G; Aretini P; Sensi E; Falaschi E; Cipollini G; Bevilacqua G; Caligo MA
    Cancer Genet Cytogenet; 2006 Oct; 170(2):93-101. PubMed ID: 17011978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation.
    Gómez-García EB; Ambergen T; Blok MJ; van den Wijngaard A
    J Clin Oncol; 2005 Apr; 23(10):2185-90. PubMed ID: 15800311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and in silico analysis of BRCA1 and BRCA2 variants.
    Tommasi S; Pilato B; Pinto R; Monaco A; Bruno M; Campana M; Digennaro M; Schittulli F; Lacalamita R; Paradiso A
    Mutat Res; 2008 Sep; 644(1-2):64-70. PubMed ID: 18694767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms.
    Pettigrew C; Wayte N; Lovelock PK; Tavtigian SV; Chenevix-Trench G; Spurdle AB; Brown MA
    Breast Cancer Res; 2005; 7(6):R929-39. PubMed ID: 16280041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability.
    Lovelock PK; Wong EM; Sprung CN; Marsh A; Hobson K; French JD; Southey M; Sculley T; Pandeya N; Brown MA; Chenevix-Trench G; Spurdle AB; McKay MJ;
    Breast Cancer Res Treat; 2007 Sep; 104(3):257-66. PubMed ID: 17063265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
    Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
    J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information.
    Osorio A; Milne RL; Honrado E; Barroso A; Diez O; Salazar R; de la Hoya M; Vega A; Benítez J
    Hum Mutat; 2007 May; 28(5):477-85. PubMed ID: 17279547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families.
    Maillet P; Chappuis PO; Khoshbeen-Boudal M; Sciretta V; Sappino AP;
    Cancer Genet Cytogenet; 2006 Aug; 169(1):62-8. PubMed ID: 16875939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
    Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
    Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting.
    van der Hout AH; van den Ouweland AM; van der Luijt RB; Gille HJ; Bodmer D; Brüggenwirth H; Mulder IM; van der Vlies P; Elfferich P; Huisman MT; ten Berge AM; Kromosoeto J; Jansen RP; van Zon PH; Vriesman T; Arts N; Lange MB; Oosterwijk JC; Meijers-Heijboer H; Ausems MG; Hoogerbrugge N; Verhoef S; Halley DJ; Vos YJ; Hogervorst F; Ligtenberg M; Hofstra RM
    Hum Mutat; 2006 Jul; 27(7):654-66. PubMed ID: 16683254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
    Zhang L; Bacares R; Boyar S; Hudis C; Nafa K; Offit K
    Mutat Res; 2009 Apr; 663(1-2):84-9. PubMed ID: 19070627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families.
    Hansen Tv; Jønson L; Albrechtsen A; Andersen MK; Ejlertsen B; Nielsen FC
    Breast Cancer Res Treat; 2009 May; 115(2):315-23. PubMed ID: 18546071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
    Malacrida S; Agata S; Callegaro M; Casella C; Barana D; Scaini MC; Manoukian S; Oliani C; Radice P; Barile M; Menin C; D'Andrea E; Montagna M
    J Clin Oncol; 2008 Jan; 26(1):26-31. PubMed ID: 18165637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer.
    Wappenschmidt B; Fimmers R; Rhiem K; Brosig M; Wardelmann E; Meindl A; Arnold N; Mallmann P; Schmutzler RK
    Breast Cancer Res; 2005; 7(5):R775-9. PubMed ID: 16168123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC.
    Kim BY; Lee DG; Lee KR; Han SH; Surendran S; Han CW; Chung N
    Biochem Biophys Res Commun; 2006 Oct; 349(2):604-10. PubMed ID: 16949048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
    Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
    Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
    Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
    Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.